UCB joins Future4care!
Paris, May 12th, 2022. UCB, an international biopharmaceutical company specialized and recognized in severe diseases in immunology and neurology, joins Future4care as a new member.
The arrival of this Belgian biopharmaceutical pioneer, with more than 8,500 employees worldwide, reinforces the multidisciplinary approach sought by the founders of Future4care.
Joining Future4care illustrates UCB's commitment to a proactive approach to innovation. We share a common belief that we can’t solve the world's health challenges alone and that major breakthroughs will come from the use of new technologies and open innovation. That's why a partnership approach is at the heart of UCB's drive to discover new tools, technologies and partners to connect with patients.
Fabienne Delaplace-Lavoix, General Manager of UCB France explains that "UCB is extremely proud to join the Future4care community to accelerate the delivery of new healthcare solutions and meet new patient needs. By joining forces with dynamic companies, biotech and medtech startups and the pharmaceutical industry, we can unleash the power of innovation and invent the future of our health together. Our mission is to create value for patients. And I think we all understand that patient value calls on us to invent new possibilities."
As a member of the Future4care Selection Committee, UCB will thus play a fundamental governance role within the ecosystem to:
- Define the annual thematic and illustrations of Future4care ;
- Take part in the choice of selection criteria for the selected startups;
- Participate in setting the guidelines for the work of the Future4care Institute ;
- Contribute to the entry of new members.
UCB will also participate in the selection of startups during the various calls for projects launched every six months.
The new member will also benefit from access to the Future4care open innovation platform and a set of acculturation, collaboration and influence services.
They will also be asked to contribute to the work of the Future4care Institute.
For more information, please visit https://future4care.com
Future4care is the European accelerator for e-health startups, born from the alliance between Capgemini, Generali, Orange and Sanofi. Its objective is to accelerate the go-to-market of solutions capable of becoming European e-health champions. An ecosystem on a scale that is unique in Europe, Future4care consists of :
- A 6400m2 space in the heart of Paris (13th arrondissement) in the Biopark to best support startups in their acceleration phase;
- An open innovation platform to facilitate acculturation, collaboration and influence within the community
- An Institute, a true knowledge center that will offer programs and conferences related to digital health ;
- A reference label.
At UCB, our mission is never over - because we always aspire to find new ways to develop solutions for people living with serious diseases. We act with determination to create value and make real improvements in the lives of the people we serve, now and in the future. We are guided by our commitment to people living with serious illnesses that inspire our research and development in neurology, immunology and other areas where our expertise, innovation and ambition can address unmet needs. We build strong relationships with patients and healthcare professionals who face these diseases every day, as well as with colleagues and partners who share our passion for addressing the challenges of serious disease.
Contact presse :